• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.泰国女性分娩期开始使用洛匹那韦的产后早期药代动力学
Antimicrob Agents Chemother. 2009 May;53(5):2189-91. doi: 10.1128/AAC.01091-08. Epub 2009 Feb 23.
2
Reduced lopinavir exposure during pregnancy.孕期洛匹那韦暴露减少。
AIDS. 2006 Oct 3;20(15):1931-9. doi: 10.1097/01.aids.0000247114.43714.90.
3
Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.妊娠晚期开始使用齐多夫定/洛匹那韦/利托那韦的药代动力学和病毒学反应。
AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.
4
Lopinavir exposure with an increased dose during pregnancy.孕期洛匹那韦暴露量随剂量增加。
J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):485-91. doi: 10.1097/QAI.0b013e318186edd0.
5
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.安普那韦或福沙普那韦与洛匹那韦/利托那韦合用时，无论是否联用依非韦伦，安普那韦和洛匹那韦的药代动力学情况。
Antivir Ther. 2007;12(6):963-9.
6
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.小于6周龄婴儿中洛匹那韦/利托那韦的早期应用：药代动力学及24周安全性与疗效
Pediatr Infect Dis J. 2009 Mar;28(3):215-9. doi: 10.1097/INF.0b013e31818cc053.
7
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.沙奎那韦软胶囊联合洛匹那韦加小剂量利托那韦双重强化方案在成人人类免疫缺陷病毒感染者中的稳态药代动力学。
Antimicrob Agents Chemother. 2004 Nov;48(11):4256-62. doi: 10.1128/AAC.48.11.4256-4262.2004.
8
Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.妊娠期 4 个阶段的洛匹那韦和利托那韦的蛋白结合：对治疗指南的影响。
J Acquir Immune Defic Syndr. 2013 May 1;63(1):51-8. doi: 10.1097/QAI.0b013e31827fd47e.
9
Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.在先前接受蛋白酶抑制剂治疗的人类免疫缺陷病毒感染的儿童和青少年患者中，高剂量洛匹那韦-利托那韦联合或不联合沙奎那韦或非核苷类逆转录酶抑制剂的药代动力学。
Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83. doi: 10.1128/AAC.00224-08. Epub 2008 Jul 14.
10
Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.怀孕晚期HIV-1感染女性服用洛匹那韦/利托那韦片剂后的血药谷浓度。
Scand J Infect Dis. 2012 May;44(5):381-7. doi: 10.3109/00365548.2011.642306. Epub 2012 Jan 21.

引用本文的文献

1
No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.孕期无需调整洛匹那韦剂量：对感染HIV的孕妇和非孕妇进行的群体药代动力学及暴露-反应分析
Antimicrob Agents Chemother. 2015 Nov 2;60(1):400-8. doi: 10.1128/AAC.01197-15. Print 2016 Jan.
2
Pharmacokinetic optimization of antiretroviral therapy in pregnancy.妊娠抗逆转录病毒治疗的药代动力学优化。
Clin Pharmacokinet. 2012 Oct 1;51(10):639-59. doi: 10.1007/s40262-012-0002-0.
3
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.三种方案预防接受单次单剂量奈韦拉平分娩的 HIV 感染孕妇发生奈韦拉平耐药突变的比较。
Clin Infect Dis. 2012 Jan 15;54(2):285-93. doi: 10.1093/cid/cir798. Epub 2011 Dec 5.

本文引用的文献

1
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.单剂量替诺福韦和恩曲他滨用于降低接受产时奈韦拉平预防围产期HIV感染的女性对非核苷类逆转录酶抑制剂药物的病毒耐药性：一项开放标签随机试验。
Lancet. 2007 Nov 17;370(9600):1698-705. doi: 10.1016/S0140-6736(07)61605-5. Epub 2007 Nov 7.
2
A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults.一项关于洛匹那韦在HIV感染成人中药物动力学的患者间变异性的回顾性治疗药物监测数据库分析。
Ther Drug Monit. 2006 Oct;28(5):650-3. doi: 10.1097/01.ftd.0000245681.12092.d6.
3
Reduced lopinavir exposure during pregnancy.孕期洛匹那韦暴露减少。
AIDS. 2006 Oct 3;20(15):1931-9. doi: 10.1097/01.aids.0000247114.43714.90.
4
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.采用反相高效液相色谱法同时测定人血浆中抗艾滋病病毒药物茚地那韦、安普那韦、沙奎那韦、利托那韦、洛匹那韦、奈非那韦、奈非那韦羟基代谢物M8及奈韦拉平。
Ther Drug Monit. 2003 Jun;25(3):393-9. doi: 10.1097/00007691-200306000-00023.
5
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.ABT-378/利托那韦联合司他夫定和拉米夫定治疗初治HIV-1感染成人：48周结果
AIDS. 2001 Jan 5;15(1):F1-9. doi: 10.1097/00002030-200101050-00002.

泰国女性分娩期开始使用洛匹那韦的产后早期药代动力学

Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.

作者信息

Cressey Tim R, Van Dyke Russell, Jourdain Gonzague, Puthanakit Thanyawee, Roongpisuthipong Anuvat, Achalapong Jullapong, Yuthavisuthi Prapap, Prommas Sinart, Chotivanich Nantasak, Maupin Robert, Smith Elizabeth, Shapiro David E, Mirochnick Mark

机构信息

Harvard School of Public Health, Boston, Massachusetts, USA.

出版信息

Antimicrob Agents Chemother. 2009 May;53(5):2189-91. doi: 10.1128/AAC.01091-08. Epub 2009 Feb 23.

DOI:10.1128/AAC.01091-08
PMID:19237646
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2681511/
Abstract

Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) microg x h/ml, 11.2 (8.0 to 17.5) microg/ml, and 4.6 (1.7 to 12.5) microg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported.

摘要

孕期第三个月洛匹那韦（LPV）的药物暴露量会降低。我们报告了在分娩期间开始使用标准剂量的洛匹那韦-利托那韦（400/100毫克，每日两次）在产后即刻和早期的药代动力学情况。在16名感染人类免疫缺陷病毒的泰国女性中，分娩后41（12至74）小时时，血浆中洛匹那韦浓度-时间曲线下面积的中位数（范围）、最高浓度和最低浓度分别为99.7（66.1至180.5）微克·小时/毫升、11.2（8.0至17.5）微克/毫升和4.6（1.7至12.5）微克/毫升。所有女性在产后30天内洛匹那韦水平均达到足够水平。未报告严重不良事件。